ACOR Financial Facts

License and royalty revenue: 2.26M
Net loss per share-diluted (earnings per share): 0.28
See Full Income Statement

Property and equipment, net of accumulated depreciation: 17.09M
Deferred product revenue-Zanaflex tablets: 29.52M
See Full Balance Sheet

Acorda Therapeutics, Inc. (ACOR) Earnings

  |   Expand Research on ACOR
Next EPS Date 2/13/15 *Est. EPS Growth Rate -22.2% *Last Qtr.
Average EPS % Beat Rate +212.8% Revenue Growth Rate +24.8% *Last Qtr.
Average % Move 1-Wk after EPS +1.4% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
10/30/14 Q314 $0.28$0.05 +$0.23$106M$94.7M N/A Details
7/31/14 Q214 $0.42$0.15 +$0.27$97.13M$91.4M N/A Details
11/4/11 Q311 $0.40$0.73 -$0.33$93.03M$90.78M N/A Details
10/31/13 Q313 $0.36$0.13 +$0.23$84.92M$90.01M N/A Details
2/13/14 Q413 $0.32$0.18 +$0.14$92.59M$89.96M N/A Details
8/1/13 Q213 $0.25$0.09 +$0.16$87.05M$82.57M N/A Details
5/6/14 Q114 $0.21$0.09 +$0.12$80.52M$81.3M N/A Details
5/2/13 Q113 $0.09$0.13 -$0.04$62.3M$80.71M N/A Details